Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25459933 | 1.00 | MAPK1 (0.30) | MAPK1 | |
| SCHEMBL25764536 | 0.80 | — | — | |
| SCHEMBL22828484 | 0.80 | — | — | |
| SCHEMBL10308723 | 0.77 | TSHR (0.32) | — | |
| SCHEMBL12216229 | 0.77 | — | — | |
| SCHEMBL14003862 | 0.76 | — | — | |
| SCHEMBL20995928 | 0.76 | MAPK1 (0.42) | MAPK1 | |
| SCHEMBL13539110 | 0.76 | — | — | |
| SCHEMBL17641574 | 0.75 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL12877183 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295664-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | KORRO BIO, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230272376-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF METHYL-CPG BINDING PROTEIN 2 (MECP2) | KORRO BIO, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230272383-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) | KORRO BIO, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230272384-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1) | KORRO BIO, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230272377-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1) | KORRO BIO, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230257752-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE SYNTHETASE (ASS1) | KORRO BIO, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230212569-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF OTOFERLIN (OTOF) | KORRO BIO, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230146891-A1 | RNA-Editing Oligonucleotides and Uses Thereof | KORRO BIO, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146891-A1 | RNA-Editing Oligonucleotides and Uses Thereof | ADAR, NSUN3, NSUN2 | MAPK1 4884/4885 |
| US-20230272384-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF RETINOCHISIN 1 (RS1) | ADAR, YARS1, ADA | MAPK1 2936/4885 |
| US-20230272383-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF GAP JUNCTION PROTEIN BETA 2 (GJB2) | GJB2, ADAR, GJA1 | MAPK1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.